Radiotherapy for Oligometastases and Oligo-Recurrence of Bone in Prostate Cancer
Table 1
Patient characteristics (35 patients).
Variables
<40 Gy (n = 14)
≥40 Gy (n = 21)
Total (n = 35)
P value*
Age
72 (66–85)
70 (55–93)
71.5 (55–93)†
0.206
Baseline PSA (ng/mL)
72.0 (0.3–964)†
11.0 (0.1–142)†
34.0 (0.1–964)†
0.047
ECOG PS
0–1
8
21
29 (82.9%)
0.002
≥2
6
0
6 (17.1%)
No. of bone metastases
3 (1–5)†
2 (1–5)†
2 (1–5)†
0.218
CRPC
5 (35.7%)
2 (9.5%)
7 (20%)
0.090
Pain
Yes
9 (64.3%)
7 (33.3%)
16 (45.7%)
0.094
Spinal cord compression
Yes
2 (14.3%)
0
2 (5.7%)
0.153
Pathologic fracture
Yes
4 (28.6%)
1 (4.8%)
4 (14.3%)
0.134
Oligostatus
oligo-recurrence group
2 (14.3%)
16 (76.2%)
18 (51.4%)
0.000
Abbreviations. PSA: prostate-specific antigen; ECOG PS: Eastern Cooperative Oncology Group performance status; CRPC: castration-resistant prostate cancer. †Median (range). *Significance of difference between groups determined by chi-square test or Fisher exact test, as appropriate. P < 0.05 considered significant.